by Raymond Tel | Mar 28, 2024 | News
Sulfateq is happy to announce that a new scientific manuscript detailing the safety of SUL-138 is published in the leading journal Toxicology Reports. This manuscript details the safety, tolerability and toxicokinetic data of SUL-138, an obligatory step in drug...
by Raymond Tel | Feb 24, 2024 | News
This week, the first dosings of SUL-238 in healthy volunteers in a Phase I study marks a major milestone in the clinical development of this hibernation-derived, first-in-class drug. The phase I study investigates the safety, tolerability and pharmacokinetics after...
by Raymond Tel | Apr 7, 2023 | News
Great news! A new scientific paper has been published about the potential of a new medicine, SUL-138, to help treat sepsis. Sepsis is a serious health problem, but right now doctors can only use antibiotics and supportive care to help patients. SUL-138 targets the...
by Raymond Tel | Dec 14, 2022 | News
Alzheimer’s Disease (AD) is a complex and progressive neurodegenerative disease which is characterized by memory loss and cognitive impairment. It is one of the most prevalent neurodegenerative diseases and it is estimated that the number of patients will increase...
by Raymond Tel | Aug 1, 2022 | News
We at Sulfateq are very proud to have reached the finals out of more than twenty applications. The Innovation Award is awarded to the innovation with the most impact in the field of Life Sciences & Health. During the final on September 27, we will pitch our...
by Miquel Estevez | Mar 4, 2022 | News
Winter sleep (hibernation) offers hibernating species the possibility to survive harsh environmental conditions, such as periods of low food availability or periods of extreme low temperatures. Hibernators lower their body temperature, breathing- and heart rate and...
by Vincent Schermer | Aug 24, 2021 | News
Groningen, The Netherlands & Ankara, Turkey – Sulfateq BV, an early stage biotech company developing a group of small molecules that maintain mitochondrial health, and GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), a publicly traded company...
by Daniel | May 18, 2021 | News
Sulfateq is happy to announce that a new scientific manuscript detailing the efficacy of SUL-151 to mitigate the development of Chronic Obstructive Pulmonary Disease (COPD), was recently published in the International Journal of Molecular Sciences. This manuscript...
by Raymond Tel | Dec 14, 2020 | News
Groningen, The Netherlands & Ankara, Turkey – Sulfateq BV, an early stage biotech company developing a group of small molecules that maintain mitochondrial health, and GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), a leading speciality...
